Chinese Medicine: Subsidiary Received Approval Notification for Listing Application of Eribulin Mesylate Active Pharmaceutical Ingredient.

The announcement from Chinese Medicine Group states that its wholly-owned subsidiary, Tianfang Pharmaceutical, has received the approval and issuance of the Chemical raw materials drug for marketing application approval notice by the National Medical Products Administration. This drug is mainly used for primary hypercholesterolemia, etc. As of the date of the announcement, Tianfang Pharmaceutical has invested approximately 14.7319 million yuan in the raw materials and preparations of this drug. This approval will further expand the company's product range and improve the layout of raw materials for cardiovascular drugs.